About LAEKNA-B Company

Established in 2016, Laikai Pharmaceutical is a clinical-stage biomedical technology company dedicated to bringing novel treatments to cancer and liver fibrosis patients around the world. The company now has 2 core products and 14 innovative candidate products: the core product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor, which is expected to be used to treat ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors. Another core product, LAE001, is an androgen synthesis inhibitor that can simultaneously inhibit CYP17A1 and CYP11B2, and is expected to be used to treat prostate cancer. For core products, the company is actively promoting 1 registered clinical trial and 5 clinical trials, 3 of which are international multi-center clinical trials (MRCT), which aim to address the medical needs brought about by cancer with limited efficacy of standard therapy (SOC). Laikai Pharmaceutical currently has 176 patents and patent applications (including authorized introduction patents and patent applications with global rights). In the field of independent research and development, Laikai Pharmaceutical's main direction is to treat cancer and liver fibrosis by coordinating human immunity.